'Get in early'; Biofilm and wax moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages

Frontiers in Microbiology

Volumn 7, Issue AUG, 2016, Pages

  Nale, Janet Y ^a   Chutia, Mahananda ^b   Carr, Philippa ^a   Hickenbotham, Peter T ^a   Clokie, Martha R J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Central Muga Eri Research and Training Institute   (India)

Author keywords

Bacteriophage therapy; Bacteriophages; Biofilms; Clostridium difficile; Clostridium difficile infection; Galleria mellonella

Indexed keywords

CLINDAMYCIN; VANCOMYCIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BACTERIOPHAGE; BIOFILM; CELL COUNTING; CLOSTRIDIUM DIFFICILE INFECTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; GALLERIA MELLONELLA; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; TOPOGRAPHY; TURBIDITY;

EID: 84989282220     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.01383     Document Type: Article

References (79)

1. Abbasifar, R., Kropinski, A. M., Sabour, P. M., Chambers, J. R., Mackinnon, J., Malig, T., et al. (2014). Efficiency of bacteriophage therapy against Cronobacter sakazakii in Galleria mellonella (greater wax moth) larvae. Arch. Virol. 159, 2253-2261. doi: 10.1007/s00705-014-2055-x
2. Abedon, S. T. (2016). Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets? FEMS Microbiol. Lett. 363:fnv246. doi: 10.1093/femsle/fnv246
3. Abedon, S. T., Kuhl, S. J., Blasdel, B. G., and Kutter, E. M. (2011). Phage treatment of human infections. Bacteriophage 1, 66-85. doi: 10.4161/bact.1.2.15845
4. Akerlund, T., Persson, I., Unemo, M., Noren, T., Svenungsson, B., Wullt, M., et al. (2008). Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J. Clin. Microbiol. 46, 1530-1533. doi: 10.1128/JCM.01964-07
5. Aperis, G., Beth, B. F., Anderson, C. A., Warner, J. E., Calderwood, S. B., and Mylonakis, E. (2007). Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain. Microbes Infect. 9, 729-734. doi: 10.1016/j.micinf.2007.02.016
6. Aslam, S., Hamill, R. J., and Musher, D. M. (2005). Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 5, 549-557. doi: 10.1016/S1473-3099(05)70215-2
7. Bartsch, S. M., Umscheid, C. A., Fishman, N., and Lee, B. Y. (2013). Is fidaxomicin worth the cost? An economic analysis. Clin. Infect. Dis. 57, 555-561. doi: 10.1093/cid/cit346
8. Bassères, E., Endres, B. T., Khaleduzzaman, M., Miraftabi, F., Alam, M. J., Vickers, R. J., et al. (2016). Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J. Antimicrob. Chemother. 71, 1245-1251. doi: 10.1093/jac/dkv498
9. Beeton, M. L., Alves, D. R., Enright, M. C., and Jenkins, A. T. A. (2015). Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model. Int. J. Antimicrob. Agents 46, 196-200. doi: 10.1016/j.ijantimicag.2015.04.005
10. Best, E. L., Freeman, J., and Wilcox, M. H. (2012). Models for the study of Clostridium difficile infection. Gut Microbes 3, 145-167. doi: 10.4161/gmic.19526
11. Borriello, S. P., Davies, H. A., and Barclay, F. E. (1988). Detection of fimbriae amongst strains of Clostridium difficile. FEMS Microbiol. Lett. 49, 65-67. doi: 10.1111/j.1574-6968.1988.tb02683.x
12. Branda, S. S., Vik,Å., Friedman, L., and Kolter, R. (2005). Biofilms: the matrix revisited. Trends Microbiol. 13, 20-26. doi: 10.1016/j.tim.2004.11.006
13. Brüssow, H. (2012). What is needed for phage therapy to become a reality in Western medicine? Virology 434, 138-142. doi: 10.1016/j.virol.2012.09.015
14. Burns, D. A., Heeg, D., Cartman, S. T., and Minton, N. P. (2011). Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS ONE 6:e24894. doi: 10.1371/journal.pone.0024894
15. Burns, D. A., and Minton, N. P. (2011). Sporulation studies in Clostridium difficile. J. Microbiol. Methods 87, 133-138. doi: 10.1016/j.mimet.2011.07.017
16. Carter, G. P., Lyras, D., Allen, D. L., Mackin, K. E., Howarth, P. M., O'connor, J. R., et al. (2007). Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J. Bacteriol. 189, 7290-7301. doi: 10.1128/JB.00731-07
17. Chan, B. K., and Abedon, S. T. (2015). Bacteriophages and their enzymes in biofilm control. Curr. Pharm. Des. 21, 85-99. doi: 10.2174/1381612820666140905112311
18. Chilton, C. H., Crowther, G. S., Freeman, J., Todhunter, S. L., Nicholson, S., Longshaw, C. M., et al. (2014). Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J. Antimicrobi. Chemother. 69, 451-462. doi: 10.1093/jac/dkt347
19. Cos, P., Tote, K., Horemans, T., and Maes, L. (2010). Biofilms: an extra hurdle for effective antimicrobial therapy. Curr. Pharm. Des. 16, 2279-2295. doi: 10.2174/138161210791792868
20. Crawford, T., Huesgen, E., and Danziger, L. (2012). Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am. J. Health Syst. Pharm. 69, 933-943. doi: 10.2146/ajhp110371
21. Dalmasso, M., De Haas, E., Neve, H., Strain, R., Cousin, F. J., Stockdale, S. R., et al. (2015). Isolation of a novel phage with activity against Streptococcus mutans biofilms. PLoS ONE 10:e0138651. doi: 10.1371/journal.pone.0138651
22. Dapa, T., Leuzzi, R., Ng, Y. K., Baban, S. T., Adamo, R., Kuehne, S. A., et al. (2013). Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J. Bacteriol. 195, 545-555. doi: 10.1128/JB.01980-12
23. Dawson, L. F., Valiente, E., Faulds-Pain, A., Donahue, E. H., and Wren, B. W. (2012). Characterisation of Clostridium difficile biofilm formation, a role for Spo0A. PLoS ONE 7:e50527. doi: 10.1371/journal.pone.0050527
24. Desbois, A. P., and Coote, P. J. (2011). Wax moth larva (Galleria mellonella): an in vivo model for assessing the efficacy of antistaphylococcal agents. J. Antimicrob. Chemother. 66, 1785-1790. doi: 10.1093/jac/dkr198
25. EBI Food Safety (2007). FDA and USDA Extend GRAS Approval for LISTEX for All Food Products. Available at: http://www.ebifoodsafety.com/en/news-2007.aspx [Accessed January 10th, 2009]
26. Fedhila, S., Buisson, C., Dussurget, O., Serror, P., Glomski, I. J., Liehl, P., et al. (2010). Comparative analysis of the virulence of invertebrate and mammalian pathogenic bacteria in the oral insect infection model Galleria mellonella. J. Invertebr. Pathol. 103, 24-29. doi: 10.1016/j.jip.2009.09.005
27. Freeman, J., Bauer, M. P., Baines, S. D., Corver, J., Fawley, W. N., Goorhuis, B., et al. (2010). The Changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 23, 529-549. doi: 10.1128/CMR.00082-09
28. Fu, W., Forster, T., Mayer, O., Curtin, J. J., Lehman, S. M., and Donlan, R. M. (2010). Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob. Agents Chemother. 54, 397-404. doi: 10.1128/AAC.00669-09
29. Ghaffar, N. M., Connerton, P. L., and Connerton, I. F. (2015). Filamentation of Campylobacter in broth cultures. Front. Microbiol. 6:657. doi: 10.3389/fmicb.2015.00657
30. 2 mediates transduction of Tn6215, encoding erythromycin resistance, between Clostridium difficile strains. MBio 4:e00840-13, doi: 10.1128/mBio.00840-13
31. Govind, R., Fralick, J. A., and Rolfe, R. D. (2011). In vivo lysogenization of a Clostridium difficile bacteriophage FCD119. Anaerobe 17, 125-129. doi: 10.1016/j.anaerobe.2011.05.012
32. Govind, R., Vediyappan, G., Rolfe, R. D., Dupuy, B., and Fralick, J. A. (2009). Bacteriophage-mediated toxin gene regulation in Clostridium difficile. J. Virol. 83, 12037-12045. doi: 10.1128/JVI.01256-09
33. Hagens, S., and Loessner, M. J. (2010). Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr. Pharm. Biotechnol. 1, 58-68. doi: 10.2174/138920110790725429
34. Hamm, E. E., Voth, D. E., and Ballard, J. D. (2006). Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc. Natl. Acad. Sci. U.S.A. 103, 14176-14181. doi: 10.1073/pnas.0604725103
35. Hargreaves, K. R., and Clokie, M. R. J. (2014). Clostridium difficile phages: still difficult? Front. Microbiol. 5:184. doi: 10.3389/fmicb.2014.00184
36. Hargreaves, K. R., Kropinski, A. M., and Clokie, M. R. J. (2014). What does the talking?: quorum sensing signalling genes discovered in a bacteriophage genome. PLoS ONE 9:e85131. doi: 10.1371/journal.pone.0085131
37. Hill, L., Veli, N., and Coote, P. J. (2014). Evaluation of Galleria mellonella larvae for measuring the efficacy and pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection. Int. J. Antimicrob. Agents 43, 254-261. doi: 10.1016/j.ijantimicag.2013.11.001
38. Indra, A., Schmid, D., Huhulescu, S., Simons, E., Hell, M., Stickler, K., et al. (2015). Clostridium difficile ribotypes in Austria: a multicenter, hospital-based survey. Wien. Klin. Wochenschr. 127, 587-593. doi: 10.1007/s00508-015-0808-5
39. Jonczyk, E., Klak, M., Miedzybrodzki, R., and Gorski, A. (2011). The influence of external factors on bacteriophages-review. Folia Microbiol. 56, 191-200. doi: 10.1007/s12223-011-0039-8
40. Justice, S. S., Hunstad, D. A., Cegelski, L., and Hultgren, S. J. (2008). Morphological plasticity as a bacterial survival strategy. Nat. Rev. Microbiol. 6, 162-168. doi: 10.1038/nrmicro1820
41. Kohanski, M. A., Dwyer, D. J., and Collins, J. J. (2010). How antibiotics kill bacteria: from targets to networks. Nat. Rev. Microbiol. 8, 423-435. doi: 10.1038/nrmicro2333
42. Kumari, S., Harjai, K., and Chhibber, S. (2011). Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J. Med. Microbiol. 60, 205-210. doi: 10.1099/jmm.0.018580-0
43. Lanis, J. M., Barua, S., and Ballard, J. D. (2010). Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog. 6:e1001061. doi: 10.1371/journal.ppat.1001061
44. Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., et al. (2015). Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825-834. doi: 10.1056/NEJMoa1408913
45. Löfmark, S., Edlund, C., and Nord, C. E. (2010). Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin. Infect. Dis. 50, S16-S23. doi: 10.1086/647939
46. Lyerly, D. M., Krivan, H. C., and Wilkins, T. D. (1988). Clostridium difficile: its disease and toxins. Clin. Microbiol. Rev. 1, 1-18. doi: 10.1128/CMR.1.1.1
47. Lyras, D., O'connor, J. R., Howarth, P. M., Sambol, S. P., Carter, G. P., Phumoonna, T., et al. (2009). Toxin B is essential for virulence of Clostridium difficile. Nature 458, 1176-1179. doi: 10.1038/nature07822
48. Mayer, M., and Narbad, A. (2012). Novel Polypeptides Having Endolysin Activity and Uses Thereof. Patent No WO 2010136754 A1
49. Mayer, M. J., Narbad, A., and Gasson, M. J. (2008). Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J. Bacteriol. 190, 6734-6740. doi: 10.1128/JB.00686-08
50. McFarland, L. V. (2009). Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr. Opin. Gastroenterol. 25, 24-35. doi: 10.1097/MOG.0b013e32831da7c4
51. Meader, E., Mayer, M. J., Gasson, M. J., Steverding, D., Carding, S. R., and Narbad, A. (2010). Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 16, 549-554. doi: 10.1016/j.anaerobe.2010.08.006
52. Meader, E., Mayer, M. J., Steverding, D., Carding, S. R., and Narbad, A. (2013). Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 22, 25-30. doi: 10.1016/j.anaerobe.2013.05.001
53. Miyata, S., Casey, M., Frank, D. W., Ausubel, F. M., and Drenkard, E. (2003). Use of the Galleria mellonella caterpillar as a model host to study the role of the Type III secretion system in Pseudomonas aeruginosa pathogenesis. Infect. Immun. 71, 2404-2413. doi: 10.1128/IAI.71.5.2404-2413.2003
54. Morten, T. R., Peter, O. J., Niels, H., Michael, G., Tim, T., and Thomas, B. (2011). The Implication of Pseudomonas aeruginosa biofilms in infections. Inflamm. Allergy Drug Targets 10, 141-157. doi: 10.2174/187152811794776222
55. Mukherjee, K., Altincicek, B., Hain, T., Domann, E., Vilcinskas, A., and Chakraborty, T. (2010). Galleria mellonella as a model system for studying Listeria pathogenesis. Appl. Environ. Microbiol. 76, 310-317. doi: 10.1128/AEM.01301-09
56. Mukherjee, K., Hain, T., Fischer, R., Chakraborty, T., and Vilcinskas, A. (2013). Brain infection and activation of neuronal repair mechanisms by the human pathogen Listeria monocytogenes in the lepidopteran model host Galleria mellonella. Virulence 4, 324-332. doi: 10.4161/viru.23629
57. Nale, J. Y., Spencer, J., Hargreaves, K. R., Buckley, A. M., Trzepiñski, P., Douce, G. R., et al. (2016). Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob. Agents Chemother. 60, 968-981. doi: 10.1128/AAC.01774-15
58. Olson, M. R., Axler, R. P., and Hicks, R. E. (2004). Effects of freezing and storage temperature on MS2 viability. J. Virol. Methods 122, 147-152. doi: 10.1016/j.jviromet.2004.08.010
59. Olszak, T., Zarnowiec, P., Kaca, W., Danis-Wlodarczyk, K., Augustyniak, D., Drevinek, P., et al. (2015). In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients. Appl. Microbiol. Biotechnol. 99, 6021-6033. doi: 10.1007/s00253-015-6492-6
60. Osman, S., Taylor, K. A., Allcock, N., Rainbow, R. D., and Mahaut-Smith, M. P. (2016). Detachment of surface membrane invagination systems by cationic amphiphilic drugs. Sci. Rep. 6:18536. doi: 10.1038/srep18536
61. Parasion, S., Kwiatek, M., Gryko, R., Mizak, L., and Malm, A. (2014). Bacteriophages as an alternative strategy for fighting biofilm development. Pol. J. Microbiol. 63, 137-145
62. Pepin, J. (2008). Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic? Clin. Infect. Dis. 46, 1493-1498. doi: 10.1086/587656
63. Price, A. B., Larson, H. E., and Crow, J. (1979). Morphology of experimental antibiotic-associated enterocolitis in the hamster: a model for human pseudomembranous colitis and antibiotic-associated diarrhoea. Gut 20, 467-475. doi: 10.1136/gut.20.6.467
64. Ramarao, N., Nielsen-Leroux, C., and Lereclus, D. (2012). The insect Galleria mellonella as a powerful infection model to investigate bacterial pathogenesis. J. Vis. Exp. 70:e4392. doi: 10.3791/4392
65. Ramesh, V., Fralick, J. A., and Rolfe, R. D. (1999). Prevention of Clostridium difficile-induced ileocecitis with Bacteriophage. Anaerobe 5, 69-78. doi: 10.1006/anae.1999.0192
66. Rinttilä, T., Kassinen, A., Malinen, E., Krogius, L., and Palva, A. (2004). Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J. Appl. Microbiol. 97, 1166-1177. doi: 10.1111/j.1365-2672.2004.02409.x
67. Seed, K. D., and Dennis, J. J. (2009). Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob. Agents Chemother. 53, 2205-2208. doi: 10.1128/AAC.01166-08
68. Silva, Y. J., Costa, L., Pereira, C., Cunha,Â., Calado, R., Gomes, N. C. M., et al. (2014). Influence of environmental variables in the efficiency of phage therapy in aquaculture. Microb. Biotechnol. 7, 401-413. doi: 10.1111/1751-7915.12090
69. Slopek, S., Weber-Dabrowska, B., Dabrowski, M., and Kucharewicz-Krukowska, A. (1987). Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp. 5, 569-583
70. Taj, M. K., Ling, J. X., Bing, L. L., Qi, Z., Taj, I., Hassani, T. M., et al. (2014). Effect of dilution, temperature and pH on the lysis activity of T4 phage against E. coli bl21. J. Anim. Plant Sci. 24, 1252-1255
71. Takeuchi, H., Nakazawa, T., Okamoto, T., Shirai, M., Kimoto, M., Nishioka, M., et al. (2006). Cell elongation and cell death of Helicobacter pylori is modulated by the disruption of cdrA (cell division-related gene A). Microbiol. Immunol. 50, 487-497. doi: 10.1111/j.1348-0421.2006.tb03819.x
72. Tasteyre, A., Karjalainen, T., Avesani, V., Delmee, M., Collignon, A., Bourlioux, P., et al. (2000). Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups. J. Clin. Microbiol. 38, 3179-3186
73. van der Veen, S., Van Schalkwijk, S., Molenaar, D., De Vos, W. M., Abee, T., and Wells-Bennik, M. H. J. (2010). The SOS response of Listeria monocytogenes is involved in stress resistance and mutagenesis. Microbiology 156, 374-384. doi: 10.1099/mic.0.035196-0
74. Venugopal, A. A., and Johnson, S. (2012). Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of clostridium difficile infection. Clin. Infect. Dis. 54, 568-574. doi: 10.1093/cid/cir830
75. Vindigni, S. M., and Surawicz, C. M. (2015). C. difficile infection: changing epidemiology and management paradigms. Clin. Trans. Gastroenterol. 6:e99. doi: 10.1038/ctg.2015.24
76. Viswanathan, V. K., Mallozzi, M. J., and Vedantam, G. (2010). Clostridium difficile infection: an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 1, 234-242. doi: 10.4161/gmic.1.4.12706
77. Watanakunakorn, C. (1984). Mode of action and in-vitro activity of vancomycin. J. Antimicrob. Chemother. 14, 7-18. doi: 10.1093/jac/14.suppl_D.7
78. Wiegand, P. N., Nathwani, D., Wilcox, M. H., Stephens, J., Shelbaya, A., and Haider, S. (2012). Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J. Hosp. Infect. 81, 1-14. doi: 10.1016/j.jhin.2012.02.004
79. Zucca, M., Scutera, S., and Savoia, D. (2013). Novel avenues for Clostridium difficile infection drug discovery. Expert Opin. Drug Discov. 8, 459-477. doi: 10.1517/17460441.2013.770466